Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.

CONCLUSIONS Our results indicate that dapagliflozin has high efficiency and low toxicity and could be a new therapeutic target for RCC.
PMID: 28763435 [PubMed - in process]

Source: Medical Science Monitor - August 3, 2017 Category: Research Tags: Med Sci Monit Source Type: research